Tango Therapeutics Announces Initial Data From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Revolution Medicines' RAS(ON) Inhibitors In Patients With MTAP-Deleted And RAS-Mutant Metastatic PDAC

뉴스 본문을 불러오고 있어요.

Tango Therapeutics Announces Initial Data From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Revolution Medicines' RAS(ON) Inhibitors In Patients With MTAP-Deleted And RAS-Mutant Metastatic PDAC | 웨이프 WAPE

Tango Therapeutics Announces Initial Data From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Revolution Medicines' RAS(ON) Inhibitors In Patients With MTAP-Deleted And RAS-Mutant Metastatic PDAC

기사 요약

관련 종목

댓글 —